Collegium Pharmaceutical, Inc. Research and Development Expense
Collegium Pharmaceutical, Inc. (COLL) reported Research and Development Expense of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. research and development expense for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. research and development expense for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. research and development expense for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. research and development expense for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. research and development expense for fiscal 2024 was $0.00.
- Collegium Pharmaceutical, Inc. research and development expense for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Collegium Pharmaceutical, Inc. research and development expense for fiscal 2022 was $3.98M, a 57.86% decline from fiscal 2021.
- Collegium Pharmaceutical, Inc. research and development expense for fiscal 2021 was $9.45M, a 3.28% decline from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | $3.98M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $3.98M 10-Q · filed 2023-11-07 | $1.61M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2022-06-30 | $0.00 10-K · filed 2023-02-23 | $3.98M 10-Q · filed 2023-08-03 | $1.61M derived: sum of 3 quarters · filed 2026-02-26 | $3.06M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2022-03-31 | $0.00 10-K · filed 2026-02-26 | $3.98M 10-Q · filed 2022-05-10 | $1.61M derived: sum of 2 quarters · filed 2026-02-26 | $3.06M derived: sum of 3 quarters · filed 2026-02-26 | $6.52M derived: sum of 4 quarters · filed 2026-02-26 |
| 2021-12-31 | $1.61M 10-K · filed 2023-02-23 | $3.06M derived: sum of 2 quarters · filed 2023-02-23 | $6.52M derived: sum of 3 quarters · filed 2023-02-23 | $9.45M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $1.45M 10-K · filed 2023-02-23 | $4.91M derived: sum of 2 quarters · filed 2023-02-23 | $7.84M 10-Q · filed 2022-11-03 | $10.31M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $3.46M 10-K · filed 2023-02-23 | $6.39M 10-Q · filed 2022-08-04 | $8.86M derived: sum of 3 quarters · filed 2023-02-23 | $11.01M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $2.93M 10-K · filed 2023-02-23 | $5.40M derived: sum of 2 quarters · filed 2023-02-23 | $7.54M derived: sum of 3 quarters · filed 2023-02-23 | $10.04M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $2.47M 10-K · filed 2022-02-24 | $4.61M derived: sum of 2 quarters · filed 2022-02-24 | $7.11M derived: sum of 3 quarters · filed 2022-02-24 | $9.77M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $2.14M 10-K · filed 2022-02-24 | $4.63M derived: sum of 2 quarters · filed 2022-02-24 | $7.30M 10-Q · filed 2021-11-04 | $9.70M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $2.49M 10-K · filed 2022-02-24 | $5.16M 10-Q · filed 2021-08-05 | $7.56M derived: sum of 3 quarters · filed 2022-02-24 | $10.05M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $2.67M 10-K · filed 2022-02-24 | $5.06M derived: sum of 2 quarters · filed 2022-02-24 | $7.55M derived: sum of 3 quarters · filed 2022-02-24 | $10.01M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $2.40M 10-K · filed 2021-02-25 | $4.89M derived: sum of 2 quarters · filed 2021-02-25 | $7.35M derived: sum of 3 quarters · filed 2021-02-25 | $10.34M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $2.49M 10-K · filed 2021-02-25 | $4.95M derived: sum of 2 quarters · filed 2021-02-25 | $7.94M 10-Q · filed 2020-11-05 | $10.19M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $2.46M 10-K · filed 2021-02-25 | $5.45M 10-Q · filed 2020-08-05 | $7.70M derived: sum of 3 quarters · filed 2021-02-25 | $9.61M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $2.99M 10-K · filed 2021-02-25 | $5.24M derived: sum of 2 quarters · filed 2021-02-25 | $7.15M derived: sum of 3 quarters · filed 2021-02-25 | $9.38M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $2.25M 10-K · filed 2020-02-27 | $4.16M derived: sum of 2 quarters · filed 2020-02-27 | $6.39M derived: sum of 3 quarters · filed 2020-02-27 | $8.66M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $1.91M 10-K · filed 2020-02-27 | $4.14M derived: sum of 2 quarters · filed 2020-02-27 | $6.41M 10-Q · filed 2019-11-06 | $8.61M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $2.24M 10-K · filed 2020-02-27 | $4.50M 10-Q · filed 2019-08-07 | $6.70M derived: sum of 3 quarters · filed 2020-02-27 | $8.77M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $2.27M 10-K · filed 2020-02-27 | $4.46M derived: sum of 2 quarters · filed 2020-02-27 | $6.53M derived: sum of 3 quarters · filed 2020-02-27 | $8.71M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $2.19M 10-K · filed 2019-02-27 | $4.26M derived: sum of 2 quarters · filed 2019-02-27 | $6.44M derived: sum of 3 quarters · filed 2019-02-27 | $8.57M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $2.07M 10-K · filed 2019-02-27 | $4.25M derived: sum of 2 quarters · filed 2019-02-27 | $6.38M 10-Q · filed 2018-11-08 | $9.71M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $2.18M 10-K · filed 2019-02-27 | $4.31M 10-Q · filed 2018-08-08 | $7.64M derived: sum of 3 quarters · filed 2019-02-27 | $10.89M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $2.13M 10-K · filed 2019-02-27 | $5.46M derived: sum of 2 quarters · filed 2019-02-27 | $8.71M derived: sum of 3 quarters · filed 2019-02-27 | $13.02M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $3.33M 10-K · filed 2018-03-07 | $6.58M derived: sum of 2 quarters · filed 2018-03-07 | $10.89M derived: sum of 3 quarters · filed 2018-03-07 | $14.95M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $3.25M 10-K · filed 2018-03-07 | $7.55M derived: sum of 2 quarters · filed 2018-03-07 | $11.62M 10-Q · filed 2017-11-08 | $13.15M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-06-30 | $4.30M 10-K · filed 2018-03-07 | $8.36M 10-Q · filed 2017-08-09 | $9.89M derived: sum of 3 quarters · filed 2018-03-07 | $13.25M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-03-31 | $4.06M 10-K · filed 2018-03-07 | $5.59M derived: sum of 2 quarters · filed 2018-03-07 | $8.95M derived: sum of 3 quarters · filed 2018-03-07 | $10.59M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2015-12-31 | $1.53M 10-K · filed 2017-03-10 | $4.89M derived: sum of 2 quarters · filed 2017-03-10 | $6.53M derived: sum of 3 quarters · filed 2017-03-10 | $7.97M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $3.36M 10-K · filed 2017-03-10 | $5.00M derived: sum of 2 quarters · filed 2017-03-10 | $6.44M 10-Q · filed 2016-11-10 | $8.75M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-06-30 | $1.64M 10-K · filed 2017-03-10 | $3.09M 10-Q · filed 2016-08-11 | $5.39M derived: sum of 3 quarters · filed 2017-03-10 | $11.21M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-03-31 | $1.45M 10-K · filed 2017-03-10 | $3.75M derived: sum of 2 quarters · filed 2017-03-10 | $9.57M derived: sum of 3 quarters · filed 2017-03-10 | $13.13M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2014-12-31 | $2.31M 10-K · filed 2016-03-18 | $8.13M derived: sum of 2 quarters · filed 2016-03-18 | $11.69M derived: sum of 3 quarters · filed 2016-03-18 | $14.96M 10-K · filed 2017-03-10 | |
| 2014-09-30 | $5.82M 10-K · filed 2016-03-18 | $9.38M derived: sum of 2 quarters · filed 2016-03-18 | $12.65M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $3.56M 10-K · filed 2016-03-18 | $6.83M 10-Q · filed 2015-08-12 | |||
| 2014-03-31 | $3.27M 10-K · filed 2016-03-18 | ||||
| 2013-12-31 | $14.16M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |